VIZIMPRO 30 MG
Country: Israel
Language: English
Source: Ministry of Health
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
DACOMITINIB AS MONOHYDRATE
Available from:
PFIZER PHARMACEUTICALS ISRAEL LTD
ATC code:
L01XE47
Pharmaceutical form:
FILM COATED TABLETS
Composition:
DACOMITINIB AS MONOHYDRATE 30 MG
Administration route:
PER OS
Prescription type:
Required
Manufactured by:
PFIZER MANUFACTURING DEUTSCHLAND GMBH, GERMANY
Therapeutic area:
DACOMITINIB
Therapeutic indications:
Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.
Authorization date:
2021-11-15
